News from PCT Europe
CROs will swipe the "lion's share" of clinical development work: predicts PCT panel
CROs must swipe the lion’s share of clinical development work from Big Pharma for innovation to happen, according to a PCT panel.
Archives for November 19, 2012
Micromacinazione to get bigger through Neo-Micro deal
Micromacinazione has bought the micronization arm of Switzerland’s Neo-Micro AG, citing growth in the API sector as the key driver for the move.
News from Dendreon, Shire and Targacept – People on the move
in-PharmaTechnologist.com presents its weekly round-up of the latest appointments in the pharmaceutical industry, including news from Dendreon, Shire and Targacept.
Sponsors waste millions collecting 'non-core' data says study
More analysis suggests that collecting data for non-core endpoints costs individual sponsors millions per clinical trial and the industry billions each year.
Could new nanotech be the first to treat MS without affecting immune system?
Researchers believe a new nanoparticle could provide the first MS therapy that does not suppress the immune system.
Synerlab buys Lyofal and IDD-Tech Orleans
CMO Synerlab has added lyophilisation and solid dosage form development capabilities to its offering with the acquisition of LyoFal and IDD-Tech Orleans.
CQC oversight would be negative for preclinical CROs, says Human Tissue Authority
UK Government proposals to hand oversight of tissue handling to a non-specialist body would have a negative impact on the preclinical services sector says the Human Tissue Authority.